Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ardea Earns Bayer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ardea Earns Bayer Milestone

Initiates second phase of Phase I/II study

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ardea Biosciences has earned a $7.5 million milestone from Bayer HealthCare under an April 2009 license agreement to develop and commercialize Ardea’s mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications.
 
The milestone was triggered by the initiation of the second phase of a previously reported Phase I/II study evaluating BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics